Managing Patients with Poor Ovarian Reserve: Strategies and Success Rates

Overview

Dyslipidemia management has evolved significantly with the introduction of PCSK9 inhibitors, offering new hope for patients who are at high risk for cardiovascular events. Join us for an in-depth webinar focused on the role of PCSK9 inhibitors in managing dyslipidemia, particularly in patients with severe hypercholesterolemia, statin intolerance, or those who are unable to reach target LDL-C levels with conventional therapies.